Testing for Liver Cancer

Transforming Liver Cancer Screening with Proactive Diagnostics

Liver cancer is one of the fastest‑rising cancer types in the UK, often diagnosed at an advanced stage because early symptoms are subtle or absent. Early detection significantly improves survival rates, yet traditional screening methods typically identify liver cancer only once a tumour has formed. This limits opportunities for early intervention. Tzar Labs aims to shift this paradigm by introducing a proactive diagnostic approach that identifies cancer risk at the molecular level, long before structural changes appear on imaging.

The HrC test represents a new generation of liver cancer screening—one that prioritises prevention, precision, and early action. By analysing cancer‑initiating cells circulating in the bloodstream, the test offers earlier and clearer insights into liver cancer risk than conventional methods alone.

Current Methods for Diagnosing Liver Cancer

Liver cancer screening and diagnosis in the UK typically involve several established tools used within the NHS and private healthcare settings:

• Ultrasound Scans: Often used for routine monitoring in high‑risk individuals, such as those with cirrhosis or chronic hepatitis.
• MRI or CT Scans: Advanced imaging used to investigate suspicious lesions and assess tumour characteristics.
• AFP Blood Test (Alpha‑fetoprotein): A biomarker test sometimes used alongside imaging, though not always reliable on its own.
• Biopsy: Tissue samples collected to confirm malignancy and determine cancer type.

These methods have been essential in improving outcomes, yet they remain reactive—they detect cancer only after visible changes occur.

Limitations of Conventional Liver Cancer Screening

Despite their value, traditional diagnostic tools present several challenges that can delay or complicate early detection:

• Detection Threshold: Imaging can only identify tumours once they reach a detectable size, meaning the earliest molecular changes remain hidden.
• False Positives: Benign liver lesions, fatty liver disease, and inflammation can mimic cancer on imaging, leading to unnecessary follow‑up tests and anxiety.
• Invasiveness: Liver biopsies carry risks such as bleeding, infection, and discomfort.
• Limited Screening Eligibility: In the UK, routine liver cancer screening is typically offered only to high‑risk groups, meaning many cases may go undetected until symptoms appear.

These limitations highlight the need for a diagnostic tool that identifies cancer risk before a tumour forms.

The HrC Test: A Breakthrough in Early Liver Cancer Detection

The HrC test introduces a transformative approach to liver cancer screening by focusing on the earliest biological drivers of cancer. Instead of searching for tumours, the test isolates and analyses Cancer Stem Cells (CSCs)—the rare cells responsible for initiating cancer development.

A simple 12ml blood sample enables the HrC test to deliver:

• A 12–18 Month Early Warning Window: Detection of cancer‑initiating molecular activity long before imaging or biopsy can identify a mass.
• High Sensitivity and Clear Results: With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous outcomes.
• Reliable “Safe Zone” Assessment: A clear indication of “no risk” offers reassurance that liver cancer is not present and is unlikely to develop within the next year.

This proactive approach empowers individuals with earlier insights and greater control over their long‑term health.

Comprehensive Cancer Screening Through a Single Test

Pan‑Cancer Detection for Complete Health Protection

Although this document focuses on liver cancer, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.

Key Advantages Include:

• Holistic Health Monitoring: Simultaneous assessment of liver cancer risk alongside other major cancers such as Bladder, Bowel, Breast, Cervical, Kidney, Leukaemia, Lung, Lymphoma, Ovarian, Pancreatic and Prostate.
• Actionable Insights: Early detection supports timely medical evaluation, lifestyle changes, and preventive strategies.
• One Test, Broad Coverage: A single, non‑invasive test that enhances long‑term health planning and peace of mind.

Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.

About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here